Hematologic Malignancy
Marginal Zone Lymphoma
CI-CAN-00008022MZBCL · MZLExplore in graph →
Hematologic111 active trials3 approved drugs
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008022MZBCL · MZLExplore in graph →
Clinical trials
407 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (79)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT00210327 | VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy | completed | Phase 2 | 33 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 |
| Jul 22, 2009 |
| clinicaltrials |
| NCT00373646 | Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients | completed | Phase 2 | 8 | Medical University of ViennaOTHER | 1 | Jun 18, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Aug 9, 2010source: clinicaltrials